Search the Newsreel

Amphenol Corporation (APH) Rebounds as Investors Look Past Copper Displacement Fears

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Asset Fund". A copy of the letter can be downloaded here. U.S. equities reached new highs in Q2, mainly driven by a narrow group of stocks benefiting from AI …

Lead Independent Director Richard Prins Sold A Bunch Of Shares In Amphastar Pharmaceuticals

Amphastar Pharmaceuticals' Lead Independent Director, Richard Prins, recently sold US$162k worth of shares at an average price of US$20.30, reducing his holding by 27%. This was the largest insider sale in the past year for the company. While the sale occurred near the current …

Do Wall Street Analysts Like Amphenol Stock?

3d illustration inflation and deflation graph by Deepadesigns via Shutterstock Amphenol Corporation (APH) is a global manufacturer of electrical, electronic, and fiber-optic connectivity products. Headquartered in Wallingford, Connecticut, the company's product portfolio spans connectors, cables, antennas, sensors, and circuit boards for a wide range …

3 Reasons Investors Love Amphenol (APH)

3 Reasons Investors Love Amphenol (APH) Amphenol trades at $168 per share and has stayed right on track with the overall market, gaining 16.6% over the last six months. At the same time, the S&P 500 has returned 11.7%. Is now a good time …

Amphenol and Pilgrim Pride have been highlighted as Zacks Bull and Bear of the Day

For Immediate Release Chicago, IL – August 13, 2026 – Zacks Equity Research shares Amphenol APH as the Bull of the Day and Pilgrim's Pride PPC as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Uber Technologies UBER, WeRide …

Bull of the Day: Amphenol (APH)

Amphenol Corporation, a Zacks Rank #1 (Strong Buy), has quietly become one of the most essential companies in the artificial intelligence buildout — and one of the best-executing large caps in the entire market. While investors have fixated on the chipmakers, Amphenol supplies the …

Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. – MUN:29A

This article focuses on the enterprise value to EBITDA forward for Amphastar Pharmaceuticals, Inc. (MUN:29A) as listed on the Munich Stock Exchange. It indicates that the market is currently closed with no trades. The information is presented within the financial section of a trading …

Amphastar director Richard Prins disposes of shares valued at $161,851

Amphastar Pharmaceuticals director Richard K. Prins sold 7,973 shares of the company's common stock for $161,851. This transaction occurred on August 11, 2026, with shares priced at $20.3 each, leaving him with 29,625 shares. The sale follows the company's strong Q2 2026 revenue of …

Amphenol (APH) Stock Fair Value Edges Higher After Analyst Target Increases

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The consensus analyst price target fair value for Amphenol has shifted from US$189.39 to …

Amphenol Trades Close to 52-Week High: Should You Still Buy the Stock?

Amphenol APH shares closed at $167.23 on Aug. 11, very close to the 52-week high of $178.52 hit on June 30. APH's shares have risen 23.8% year to date (YTD), outperforming the Zacks Computer and Technology sector's appreciation of 16.9%. The outperformance can be …

Amphastar CFO William Peters sells $183,886 in company stock

Amphastar Pharmaceuticals CFO William J. Peters sold 8,180 shares of company stock for $183,886 on August 7, 2026, as part of a Rule 10b5-1 trading plan. Concurrently, he acquired 5,053 shares through employee stock option exercises for $99,998. Following these transactions, Peters beneficially owns …

Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters Sells 8,180 Shares

Amphastar Pharmaceuticals' CFO, William Peters, sold 8,180 shares of the company's stock for a total of $183,886.40, reducing his holdings by 4.52%. This transaction occurred under a pre-arranged Rule 10b5-1 trading plan. The company recently reported strong quarterly earnings, beating analyst estimates for both …

Amphastar (AMPH) CFO exercises options and sells 8,180 shares in 10b5-1 trade

Amphastar Pharmaceuticals' CFO, William J. Peters, exercised 5,053 employee stock options at $19.79 per share and subsequently sold 8,180 shares of common stock at $22.48 per share on August 7, 2026. This sale was conducted under a Rule 10b5-1 trading plan adopted on March …

AMPH (AMPH) schedules Rule 144 stock sale tied to RSU vesting

Amphastar Pharmaceuticals (AMPH) has filed a Rule 144 notice for the proposed sale of 7,973 shares of common stock, valued at $161,931.63, through UBS Financial Services Inc. The sale is scheduled for August 11, 2026, and is linked to multiple Restricted Stock Unit (RSU) …

Amphenol (APH) After Its Dividend Update And The Case For A Full Valuation

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Reduce" from Analysts

Amphastar Pharmaceuticals (NASDAQ:AMPH) has received an average "Reduce" recommendation from eight brokerages, with two analysts rating it a "sell" and six a "hold." Despite this cautious sentiment and an average 12-month price target of $22.00, the company recently surpassed earnings expectations, reporting $0.91 EPS …

Weekly Recap: Amphastar Q2 growth, $100M BAQSIMI and IMS FDA warning

Amphastar Pharmaceuticals (AMPH) reported strong Q2 2026 revenue of $183.9M, a 5% year-over-year increase, significantly boosted by a $100M payment from a $175M BAQSIMI milestone. However, the company faces potential increased remediation costs and slowed batch releases due to an FDA warning letter issued …

Results: Amphastar Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

This article provides an analysis of Amphastar Pharmaceuticals, Inc.'s recent financial performance, highlighting that the company exceeded consensus expectations. It is anticipated that analysts will update their estimates based on these strong results. The piece will likely delve into the specific financial metrics that …

Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $20.00 by Analysts at Piper Sandler

Piper Sandler has reduced its price target for Amphastar Pharmaceuticals (AMPH) to $20.00 from $21.00, maintaining a "neutral" rating despite the company's recent earnings beat. While Amphastar exceeded analyst expectations with adjusted EPS of $0.91 and revenue of $183.9 million, overall analyst sentiment remains …

Amphastar Pharmaceuticals (AMPH) Stock Rebound Meets Margin Pressure And Valuation Gap

Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded by Wall Street Zen to "Strong-Buy" Rating

Amphastar Pharmaceuticals (NASDAQ:AMPH) received an upgrade from Wall Street Zen to a "strong-buy" rating, despite a more cautious "reduce" consensus rating from other analysts. The company's recent quarterly results surpassed expectations with revenues of $183.9 million and adjusted EPS of $0.91, outperforming estimates. Institutional …

Amphastar Pharmaceuticals, Inc. SEC Filing (Aug 7, 2026)

This article reports on Amphastar Pharmaceuticals, Inc.'s SEC Form 144 filing from August 7, 2026. The filing indicates a proposed sale of securities, detailing the class of securities, the broker involved (UBS Financial Services, Inc.), the number of shares, aggregate market value, and the …

Amphastar Pharmaceuticals, Inc. (AMPH) stock price, news, quote and history

This article provides a comprehensive overview of Amphastar Pharmaceuticals, Inc. (AMPH) stock, including its current price, historical data, financial performance, and analyst ratings. It details the company's product portfolio, which includes various injectable, inhalation, and intranasal products, and lists key financial metrics and comparisons …

Amphenol Corp (APH) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Amphenol approves two-for-one stock split, updates Q3 adjusted EPS and declares Q3 dividend

Amphenol (APH) has announced a two-for-one stock split via a stock dividend, payable on September 2, 2026, with a record date of August 17, 2026. The company also updated its Q3 2026 adjusted diluted EPS guidance to $0.70–$0.71 post-split and declared a Q3 2026 …

Earnings call transcript: Amphastar rises after q2 2026 revenue beat By Investing.com

Amphastar P earnings beat by $0.28, revenue topped estimates

Amphastar Pharmaceuticals Q2 Earnings Call Highlights

Amphastar Pharmaceuticals reported a 5% year-over-year revenue increase in Q2 2026, reaching $183.9 million, driven by new product launches like ipratropium bromide inhalation. Despite a slight dip in net income, diluted EPS rose, and the company is addressing an FDA warning letter at its …

Amphastar anticipates $2M-$3M per quarter IMS remediation costs while maintaining mid-single digit to high single-digit 2026 sales growth

Earnings Call Insights: Amphastar Pharmaceuticals (AMPH) Q2 2026 MANAGEMENT VIEW * “The second quarter was marked by strong execution across each of our strategic growth pillars.” (Senior Vice President of Human Resources & Corporate Communication Dan Dischner) * “Revenue increased to approximately $184 million, …

FMR LLC discloses 5.7% Amphenol (APH) stake held through affiliated entities

FMR LLC reported a 5.7% beneficial ownership stake in Amphenol Corporation's Class A common stock, totaling 70,486,300.18 shares as of June 30, 2026, via an Amendment No. 27 to a Schedule 13G filing. Abigail P. Johnson is also reported with the same beneficial ownership, …

Earnings call transcript: Amphastar rises after q2 2026 revenue beat

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates

Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported better-than-expected Q2 CY2026 results, with revenue of $183.9 million exceeding analyst estimates by 2% and non-GAAP profit of $0.91 per share significantly beating consensus estimates. The company achieved 5.4% year-on-year revenue growth and highlighted successful key goals including overall revenue …